Skip to content

ASTENZ – A Preliminary Feasibility Study to Evaluate an Interactive Online Application in Advanced Cancer

ASTENZ – A Preliminary Feasibility Study to Evaluate an Interactive Online Application in Advanced Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037577
Enrollment
171
Registered
2026-01-13
Start date
2026-02-12
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C97

Interventions

Group 1: Use of the app for four/eight weeks Group 2: Treatment as Usual (TAU)

Sponsors

Deutsche Krebshilfe
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive Surprise Question, sufficient knowledge of the German language, capacity to provide informed consent of patients/caregivers, consent to participate

Exclusion criteria

Exclusion criteria: under curative treatment

Design outcomes

Primary

MeasureTime frame
Applicability, usability, and acceptance of the app (SuS, section E from MARS-G, as well as self-developed items)

Secondary

MeasureTime frame
Subjective knowledge (self-created items), objective knowledge (self-developed items and one item from the PC-KAC Scale), trust (self-developed items), readiness to engage in end-of-life conversations (REOLC), anxiety and depression (PHQ-4), current distress (Distress Thermometer), quality of life (FACT-G), number of consultations, automated study-ID–based recording of usage statistics (number of page views, dwell time, dropout rates per video via MATOMO), accompanying qualitative interviews and focus groups on app usage

Countries

Germany

Contacts

Public ContactPia von Blanckenburg

Arbeitseinheit Klinische Psychologie und Psychotherapie, Philipps-Universität Marburg

pia.vonblanckenburg@uni-marburg.de+49 6421 2824051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jul 19, 2026